Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Herbal ingredient (B)
- Development stage
- Preclinical
- Lead developer
- Korea Pharma
- Administration
- Oral, Topical
01
Overview
Herbal ingredient (B) is a botanical-based therapeutic candidate currently in preclinical development by Korea Pharma for the treatment of eczema. Part of the company's research into traditional Korean medicine (Hanbang) components, this asset is being evaluated for its potential to alleviate symptoms of inflammatory skin disease. Specific details regarding its phytochemical composition or molecular targets have not been publicly disclosed by the sponsor.
- Other names
- 한방성분(B)
02
Targets
ATF4 (Activating transcription factor 4)JNK (Mitogen-activated protein kinase kinase kinase family)NF-κBSFK (SRC family kinases)SYK (Spleen Tyrosine Kinase)TAK1 (Transforming growth factor beta–activated kinase 1)RK (Ribokinase)
Beyond the preview
Go deeper on Herbal ingredient (B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Herbal ingredient (B).